Cellaria

Cellply is a deep tech company with the ambition to develop analytical tools enabling fast end effective development of life-saving cancer cell therapies. Our team features a unique combination of expertise in a diverse set of technology going from microfluidics to robotics, AI, biology and immunology. During Advanced Therapies Week 2024 in Miami we officially launched our flagship product, VivaCyte®.

We are the change and it is happening now. We are pushing the boundaries of what is possible and leading a revolution in healthcare. Nested deep in our molecular coding, is a universe of biological networks that provide the source of life. This convergence of sequencing power, big data and AI technologies provides an unmatched resource to develop the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. With a primary focus on cancer, Caris has built a market-leading portfolio of precision medicine tools that have helped more than half a million cancer patients worldwide. Patients within the Caris RIT oncology network gain access to innovative molecular diagnostics while remaining in the care of their current treatment team, locally. Having clinical trials on-demand in TrialPlus+ connects physicians to clinical trials to deliver breakthrough cancer medicines to their patients.

Caris Life Sciences was founded with a very simple but powerful purpose – to help improve the lives of as many people as possible. With transformative technologies, we are revolutionizing precision medicine to provide physicians and patients with the highest quality information about their health. Through tireless efforts, breakthrough molecular science and a passionate commitment to quality, we remain steadfastly focused on the most important part of our work – the patient.”. As the pioneer in precision medicine, Caris is ushering in a new era of cancer care with blood-based monitoring for patients before treatment, during treatment and after treatment. Currently available within Caris’ Precision Oncology Alliance, our pan-cancer, circulating nucleic acids sequencing (cNAS) assay combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.

Carcinotech is a MedTech company with expertise in manufacturing 3D printed living tumours using patient-derived biopsies, primary cells, immune cells and cancer stem cells. Carcinotech’s advanced models provide a platform for rapid, ethical, and accurate drug screening, pre-clinical and personalised medicine testing. Access to Carcinotech’s robotic and automated manufacturing allows for accelerated production, with models offering high-throughput capabilities. Carcinotech’s expert scientific team is available to comment on topics relating to 3D bioprinting, pre-clinical and personalised medicine testing in the oncology space. Working with global partners, leading pharma companies, surgeons, pathologists, clinicians, and industry leaders, the goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Our Carcino3D™ models offer a platform for in vitro high-throughput, accurate and rapid drug discovery and screening for novel, combinatorial and repurposed drugs. They are bioengineered to de-risk cancer drug testing and pre-clinical trials offering translational data with respect to cancer heterogeneity and microenvironments. Our advanced technology provides a platform for rapid, ethical, and accurate drug discovery, screening, and pre-clinical testing.

CanCertain utilises advanced 3D cell culture techniques to recommend personalised cancer treatments, improving patient quality of life and efficacy in eliminating cancer cells. CanCertain helps focus the current approach by testing standard chemotherapies, targeted therapies and immunotherapies, allowing the patient to receive the most effective treatment first time. Our vision is for every cancer patients’ treatment to be guided by our specialised clinical test and personalised treatment plan. We are committed to providing accurate, reliable, and validated results to inform treatment decisions for people with cancer. CanCertain Ltd was established in the UK by like-minded clinicians passionate about advancing innovative 3D cell culture techniques to identify the most effective treatment for each cancer patient. Our mission remains the same and continues to drive our long-term commitment to deliver personalised cancer treatment plans to people throughout the world. CanCertain Ltd is a UK based award-winning state of the art laboratory that uses advanced 3D cell culture techniques to identify most effective cancer treatment for a specific tumour quickly. CanCertain Ltd utilises advanced 3D cell culture techniques to recommend personalised cancer treatments, improving efficacy and the patient’s quality of life.View our test products ».

A new approach for personalizing treatments is currently in clinical trials : clinicians test potential therapies directly on patient-derived cells grown as 3D spheroids in the lab. Okomera has developed a device for automating and miniaturizing ex vivo cancer testing in 3D, on a single microfluidic chip. Our technology allows for multiplexing >30 conditions on a single chip. Also co-cultures and/or T-cell interactions can be tested. Installation of Okomera’s automated liquid handler at Institut Pasteur. (January 2022).